Ko-Chung Lin

This inventor holds 18 USPTO granted patents and 12 published patent applications, plus 4 CIPO patents and 4 EPO patents, primarily in Biopharmaceuticals. Top assignees: Biogen, Incorporated, Pharmaessentia Corporation, Biogen Idec Ma Inc.. Active years: 2001-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ko-Chung Lin. Retrieved from https://idiyas.com/inventor/ko-chung-lin-nf015fks

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 12)

% Patents Active = 66.7

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 4 (Patent Applications = 6)

Average Co-Inventor Count = 2.9

ph-index = 6

Forward Citations = 76(Granted Patents)

Company Filing History:

Pharmaessentia Corporation

Years Active: 2001-2025

Loading Chart...

Areas of Expertise:

Pegylated Interferon

5-Deoxy-5'-Fluorocytidine

Interferon-Polymer Conjugates

Protein-Polymer Conjugates

Stereoselective Synthesis

A1 Adenosine Receptor Antagonists

Cell Adhesion Inhibitors

Therapeutic Use

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12343381 - Dosage regimen for pegylated interferon (2025-07-01),

2. 11559567 - Dosage regimen for pegylated interferon (2023-01-24),

3. 8975393 - Synthesis of 5-deoxy-5'-fluorocytidine compounds (2015-03-10),

4. 8617532 - Therapeutic use of interferon-polymer conjugates (2013-12-31),

5. 8273343 - Protein-polymer conjugates (2012-09-25),

6. 8143214 - Protein-polymer conjugates (2012-03-27),

7. 7485716 - Stereoselective synthesis of β-nucleosides (2009-02-03),

8. 7022686 - A1 adenosine receptro antagonists (2006-04-04),

9. 7001921 - Cell adhesion inhibitors (2006-02-21),

10. 6875743 - Cell adhesion inhibitors (2005-04-05),

11. 6630512 - Cell adhesion inhibitors (2003-10-07),

12. 6624152 - Cell adhesion inhibitors (2003-09-23),

13. 6605601 - A1 adenosine receptor antagonists (2003-08-12),

14. 6596687 - Cell adhesion inhibitors (2003-07-22),

15. 6376538 - Cell adhesion inhibitors (2002-04-23),

Title: The Innovations of Inventor Ko-Chung Lin

Introduction

Ko-Chung Lin, based in Lexington, MA, is a prominent inventor known for his significant contributions to the field of medical innovation. With a remarkable portfolio of 17 patents, Lin has made strides in developing treatments for various diseases, particularly focusing on infectious diseases and cancer.

Latest Patents

Among his latest patents, Lin has developed a dosage regimen for pegylated interferon. This pegylated type I interferon is designed for use in treating infectious diseases, cancer, or myeloproliferative diseases. The innovative regimen involves administering a dosage of 50 to 540 μg at regular intervals of 3 to 8 weeks, tailored to meet the needs of patients. Additionally, he has invented a process for synthesizing 5-deoxy-5'-fluorocytidine compounds, detailing a reaction involving specific nucleoside compounds. This process utilizes various compounds and solvents, showcasing Lin's expertise in biochemical synthesis.

Career Highlights

Ko-Chung Lin's career is marked by significant tenures at reputable organizations. He has worked with Biogen, Incorporated, and Pharmaessentia Corporation, where he contributed his innovative ideas and research capabilities to advance medical science. His experience in these companies highlights his dedication to addressing critical health challenges through invention and research.

Collaborations

Throughout his career, Lin has collaborated with talented professionals, including coworkers Steven P. Adams and Wen-Cherng Lee. These collaborations have played an essential role in the development of his patents and further the impact of his innovations in the medical field.

Conclusion

In summary, Ko-Chung Lin stands out as a leading inventor in the realm of medical innovation. His extensive patent portfolio and collaborative efforts highlight his commitment to improving healthcare through scientific developments. As he continues to innovate, Lin's contributions to treatment methodologies will undoubtedly leave a lasting impact on the industry.

Profile summary based on public USPTO records.